Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE COLLABORATION

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that, MiRXES PTE. LTD., an indirect wholly-owned subsidiary of the Company, has recently entered into a memorandum of understanding (the "**MOU**") with PT DIASTIKA BIOTEKINDO (a company listed on the Indonesia Stock Exchange, stock code: CHEK) ("**PT DIASTIKA BIOTEKINDO**"), pursuant to which both parties agreed to collaborate on the registration and commercialization of molecular diagnostic tests and associated instruments for early detection and diagnosis of high incidence and high mortality cancers in Indonesia. The MOU has a term of 12 months from and including the date of signing.

Both parties will proceed to sign a definitive agreement upon confirming the direction of cooperation setting out the terms and conditions applicable to that Collaborative Activity (as defined below).

The principal terms of the MOU are as follows:

Major scope of collaboration

Both parties agree to cooperate in good faith, among others, the following activities (the "**Collaborative Activities**" and each a "**Collaborative Activity**"):

(a) sales and distribution of the Group's pipeline of novel blood borne circulating microRNA and multi-omic cancer early detection tests for high incidence and high mortality cancers in Indonesia, including but not limited to gastric, lung, colorectal, liver, breast, ovarian, pancreatic and prostate cancers; and registration of the above-mentioned tests as medical devices in Indonesia;

(b) joint development and clinical validation projects of mutual interest for the registration of the above-mentioned tests;

(c) conduct development and training for Indonesia scientists and laboratory users; and

(d) explore partnership for localization of manufacturing activities.

INFORMATION OF PT DIASTIKA BIOTEKINDO

PT DIASTIKA BIOTEKINDO is a company incorporated under the laws of Indonesia with limited liability and is principally engaged in the wholesale of laboratory equipment and reagents, pharmaceutical equipment and medical equipment and devices in Indonesia.

PT DIASTIKA BIOTEKINDO's hospital network with more than 300 hospitals (70% in Java, which is home to 57% of Indonesians) provides immediate scale, while underserved outer islands present a 90% untapped opportunity.

REASONS FOR ENTERING INTO THE MOU

Indonesia, Southeast Asia's largest economy with over 270 million people, offers a massive, fast-growing healthcare market fueled by a youthful demographic, rising prosperity, and increasing health awareness. The nation's cancer burden with more than 350,000 new cases annually (World Health Organization, 2022) and a 70% mortality rate (compared to that of 60% globally) stems from dire screening gaps (only 15% of gastric or lung cancer patients are diagnosed early).

By partnering with PT DIASTIKA BIOTEKINDO, the Group can (i) penetrate the Indonesian market immediately by deploying blood-based microRNA or multi-omics tests for high-incidence cancers (such as gastric, lung, etc.) via PT DIASTIKA BIOTEKINDO's established channels; (ii) gain regulatory agility by leveraging Indonesia's pro-localization policies (such as 40% domestic content threshold for tax breaks) and ASEAN-centric medical device frameworks; and (iii) archive global scalability by using Indonesia as a launchpad for replication in Southeast Asia, Middle East, North Africa, and beyond, where similar cancer profiles and healthcare structures exist.

The Board believes that entering into the MOU represents a pivotal step in the Group's internationalization strategy and its expansion into a high-potential emerging market.

Shareholders and potential investors of the Company should note that Collaborative Activities may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, August 15, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan, Dr. ZOU Ruiyang and Mr. HO Hou Chiat, Isaac as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.